Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Topokine, Allergan deal

    Topokine Therapeutics Inc., Newton, Mass. Allergan plc (NYSE:AGN), Dublin, Ireland Business: Other Allergan acquired Topokine for $85 million up front. Topokine shareholders are also eligible for development and sales …

    Published on 5/2/2016
  • TxCell, Ospedale San Raffaele deal

    TxCell S.A. (Euronext:TXCL), Valbonne, France Ospedale San Raffaele, Milan, Italy Business: Autoimmune TxCell and Ospedale partnered to develop chimeric antigen receptor (CAR) regulatory T cells to treat lupus nephritis…

    Published on 5/2/2016
  • Vertex, Enterome Bioscience deal

    Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Boston, Mass. Enterome Bioscience S.A., Paris, France Business: Autoimmune Vertex granted Enterome exclusive, worldwide rights to small molecule antagonists of bacterial …

    Published on 5/2/2016
  • Zymeworks, GlaxoSmithKline deal

    Zymeworks Inc., Vancouver, B.C. GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Business: Antibodies Zymeworks granted GlaxoSmithKline an option to license molecules developed using the biotechs Azymetric …

    Published on 5/2/2016
  • Allenex, CareDx deal

    Allenex AB, Stockholm, Sweden CareDx Inc. (NASDAQ:CDNA), Brisbane, Calif. Business: Diagnostic CareDx acquired fellow transplant diagnostic company Allenex. For each Allenex share held, majority shareholders received 0.…

    Published on 4/25/2016
  • argenx, AbbVie deal

    argenx N.V. (Euronext:ARGX), Breda, the Netherlands AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Cancer AbbVie acquired an exclusive option from argenx to license ARGX-115, a mAb against leucine-rich repeat …

    Published on 4/25/2016
  • AstraZeneca, Human Longevity, Genomics England, Wellcome Trust, University of Helsinki, Montreal Heart Institute deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Human Longevity Inc., San Diego, Calif. Genomics England Ltd., London, U.K. Wellcome Trust, London, U.K. University of Helsinki, Helsinki, Finland Montreal Heart …

    Published on 4/25/2016
  • Cellect Biomed, Accellta deal

    Cellect Biomed Ltd. (Tel Aviv:CLBD), Tel Aviv, Israel Accellta Ltd., Haifa, Israel Business: Supply/Service Cellect granted Accellta non-exclusive rights to evaluate apoptotic induction-based technology. Accellta will …

    Published on 4/25/2016
  • CutisPharma, Dr. Reddys Laboratories Ltd. deal

    CutisPharma Inc., Wilmington, Mass. Dr. Reddys Laboratories Ltd. (NYSE:RDY), Hyderabad, India Business: Pharmaceuticals The companies partnered to co-develop and commercialize CutisPharmas RM-02, RM-03 and RM-06 …

    Published on 4/25/2016
  • Dong-A ST, Tobira deal

    Dong-A ST Co. Ltd. (KSE:170900), Seoul, South Korea Tobira Therapeutics Inc. (NASDAQ:TBRA), San Francisco, Calif. Business: Endocrine/Metabolic, Hepatic Dong-A granted Tobira exclusive rights to develop and …

    Published on 4/25/2016
  • Genentech, Otsuka Pharmaceutical, Roche deal

    Genentech Inc., South San Francisco, Calif. Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Cancer Roches Genentech unit and Otsukas Astex Pharmaceuticals Inc. …

    Published on 4/25/2016
  • GlaxoSmithKline, Sanford Burnham Prebys Medical Discovery Institute deal

    GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Sanford Burnham Prebys Medical Discovery Institute, La Jolla, Calif. Business: Neurology The institute and GlaxoSmithKline partnered to create the SBP-GSK Center for …

    Published on 4/25/2016
  • Hummingbird Bioscience, Sanofi deal

    Hummingbird Bioscience Pte. Ltd., Singapore Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Cancer Hummingbird and Sanofi partnered to develop cancer antibodies using Hummingbirds Rational Antibody Design …

    Published on 4/25/2016
  • Intrexon, AmpliPhi BioSciences deal

    Intrexon Corp. (NYSE:XON), Germantown, Md. AmpliPhi Biosciences Corp. (NYSE-M:APHB), Richmond, Va. Business: Infectious AmpliPhi terminated a 2013 deal with Intrexon to develop bacteriophage-containing therapeutics to …

    Published on 4/25/2016
  • Merck, Taiho deal

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Taiho Pharmaceutical Co. Ltd., Tokyo, Japan Business: Cancer Merck granted Taiho Japanese co-promotion rights to pembrolizumab. The humanized IgG4 mAb against PD-1 is under …

    Published on 4/25/2016
  • NanoString, HalioDx deal

    NanoString Technologies Inc. (NASDAQ:NSTG), Seattle, Wash. HalioDx S.A.S., Marseille, France Business: Pharmacogenetics NanoString and HalioDx partnered to develop and commercialize cancer gene expression assays for …

    Published on 4/25/2016
  • OncBioMune Pharmaceuticals, Vitel deal

    OncBioMune Pharmaceuticals Inc. (OTCQB:OBMP), Baton Rouge, La. Vitel Laboratorios S.A. de C.V., Mexico City, Mexico Business: Cancer OncBioMune and Vitel will form the JV OncBioMune Mexico S.A. de C.V. to develop and …

    Published on 4/25/2016
  • Protein Sciences, Sinergium, Mundo Sano deal

    Protein Sciences Corp., Meriden, Conn. Sinergium Biotech, Buenos Aires, Argentina Mundo Sano Foundation, Buenos Aires, Argentina Business: Infectious The partners formed a consortium to develop a Zika virus vaccine …

    Published on 4/25/2016
  • Salus, Yabao Pharmaceutical Group deal

    Salus Pharma LLC, Monmouth Junction, N.J. Yabao Pharmaceutical Group Co. Ltd. (Shanghai:600351), Beijing, China Business: Generics Yabao and Salus partnered to develop, manufacture and commercialize complex formulations…

    Published on 4/25/2016
  • Tobira, Dong-A ST deal

    Tobira Therapeutics Inc. (NASDAQ:TBRA), San Francisco, Calif. Dong-A ST Co. Ltd. (KSE:170900), Seoul, South Korea Business: Endocrine/Metabolic, Hepatic Tobira granted Dong-A exclusive, South Korean rights to develop …

    Published on 4/25/2016
  • XL-protein, Akari Therapeutics deal

    XL-protein GmbH, Freising, Germany Akari Therapeutics plc (NASDAQ:AKTX), New York, N.Y. Business: Autoimmune, Neurology, Hematology Akari and XL-protein will apply XL-proteins PASylation technology for drug half-life …

    Published on 4/25/2016
  • Array BioPharma, Asahi Kasei Pharma deal

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. Asahi Kasei Pharma Corp., Tokyo, Japan Business: Neurology, Inflammation Array granted Asahi exclusive rights in Japan, Korea, Taiwan and China to commercialize and …

    Published on 4/18/2016
  • Astellas, Mitsubishi Tanabe Pharma deal

    Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Business: Pharmaceuticals, High throughput screening Astellas and Mitsubishi partnered to share their compound …

    Published on 4/18/2016
  • AstraZeneca, Eli Lilly deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Neurology AstraZeneca received a $100 million milestone payment under a 2014 deal to jointly develop and …

    Published on 4/18/2016
  • Epic Pharma, Humanwell Healthcare Group, PuraCap Pharmaceutical LLC deal

    Epic Pharma LLC, Laurelton, N.Y. Humanwell Healthcare Group Co. Ltd. (Shanghai:600079), Wuhan, China PuraCap Pharmaceutical LLC, South Painfield, N.J. Business: Generics Humanwell and PuraCap will acquire generic …

    Published on 4/18/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993